A new clinical trial involving vasopressin was registered on October 30, 2026. The study, titled "Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome," is listed under identifier NCT07328529.
The trial is designated as Phase 2 and its current status is not yet recruiting. This means enrollment has not yet begun as of the listed date.
According to the registration, the study aims to examine vasopressin in participants with Fragile X Syndrome, specifically in relation to aggressive behavior. No outcome data, efficacy claims, or safety findings have been reported at this stage, since the trial has not started recruiting participants.
Vasopressin itself remains an approved compound, and this registration reflects a new investigational use under study. As with any trial in the not yet recruiting phase, details such as enrollment timelines, study sites, and eligibility criteria may be subject to change before recruitment opens.
Readers interested in the broader context of vasopressin, including its approved uses and other ongoing research, can consult the compound overview for additional background.